Posts tagged as: CXM stock quote back to homepage
 |
Cardium Wins Patent Rights to Heart Disease Treatment, Settles Dispute with Boston Scientific(0) Cardium Announces Patent Award For Rights To Cardiovascular Gene Therapy For The Treatment Of Heart Disease Resolves Long-standing Competition with Boston Scientific Corporation Over Rights to Cardiovascular Gene Therapy in the U.S. and Europe Cardium Therapeutics (NYSE MKT: CXM) today announced a winning patent decision in Europe and successful resolution of a long-standing competition between Cardium and its licensor the University of California, and Boston Scientific Corporation (NYSE: BSX) and its licensor Arch Development, over rights to key methods for the application of cardiovascular gene therapy Read More |
 |
Cardium Therapeutics Excellagen Launch Timely with Rising Trend in Diabetic Foot Ulcers(0) Demographic trends towards an aging population, soaring diagnosis rates in diabetes, obesity and cardiovascular disease are just a few of the factors that are driving growth and spurring innovation to better serve millions of wound care patients each year. The wound care industry has many verticals for sales, but probably none more critical than diabetic foot ulcers. Diabetic foot ulcers affect about 15 percent of the nearly 26 million people with diabetes in the United States, and Read More |
 |
EC Approval of Glybera A Significant Industry Milestone in Gene Therapy(0) Commenting on the October 25 approval by the European Commission for its gene therapy, Glybera®, Dutch biotech company uniQure said Monday it plans to start selling Glybera in Europe by mid-2013 and predicted a boom of similar therapies. The EC approval marks Glybera as the first gene therapy to be approved in the Western world. Read More |
 |
Cardium Therapeutics Aligned in Neutraceutical Market Set to Reach $243 Billion by 2015(0) Late in September, a comprehensive report by Global Industry Analysts, Inc. stated that the global nutraceutical market will cross $243 Billion by 2015, “owing to consumer desire for leading a healthy life and increasing scientific evidence supporting health foods.” The research firm also attributes the strong growth rate to an aging population and rising healthcare costs as catalysts for the neutraceutical industry that it calls “one of the brightest spots in a global market suffering from its worst economic Read More |
 |
Excellagen Presentation on Cardium Therapeutics Website(0) An updated presentation for Excellagen has been published on the Cardium Therapeutics (NYSE MKT: CXM) website. The pdf file is available for viewing/dowloading at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations. Read More |
 |
Cardium Therapeutics Boosts Energy Supplement Sales(0) A recent article on San Diego Biotechnology Connection: Cardium boosts energy supplement sales with national marketing muscle Cardium Therapeutics’ purchase of To Go Brands and its nationwide marketing network is expected to boost energy supplement sales of Cardium’s MedPodium line, including Neo-Chill, which promotes relaxation without drowsiness and contains Suntheanine, a patented, proprietary L-theanine (an amino acid) also found in green tea. Read More |
 |
Cardium Increases Product Portfolio with Acquisition of To Go Brands(0) Cardium Therapeutics (NYSE MKT: CXM) today announced that its MedPodium® operating unit has acquired the assets, business and product portfolio of privately-held To Go Brands® to support the expansion of Cardium’s health sciences nutraceutical brand platform. To Go Brands have introduced products in a number of food, drug and mass channel retailers, and the company recorded revenues of approximately $1.7 million for the first 6 months of 2012. Read More |
 |
Cardium Forms Excellagen Medical Advisory Board for Wound Care Product(0) Cardium Therapeutics Ltd. (NYSE MKT: CXM), an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and business with the potential to address significant unmet medical needs and definable pathways to commercialization, similar to companies like Impax Laboratories Inc. (NASDAQ: IPXL) and Osiris Therapeutics Inc. (NASDAQ: OSIR), said today that they have assembled a new Excellagen Medical Advisory Board as part of corporate initiatives Read More |
 |
Cardium to Present at Rodman and Renshaw Conference(0) Cardium to Present at the Rodman & Renshaw Annual 2012 Healthcare Investment Conference Cardium Therapeutics (NYSE MKT: CXM) today announced that Christopher J. Reinhard, Chairman & CEO will present at the Rodman & Renshaw Annual Healthcare Investment Conference on Monday, September 10, 2012 at 3:15 p.m. Eastern Time. The conference is being held September 9-11, 2012 at the Waldorf-Astoria Hotel in New York City. An audio webcast of the Company’s presentation will be available live and by replay and can be accessed at Read More |
 |
Cardium and Generx Featured on San Diego Biotechnology Connection(0) An article this morning on San Diego Biotechnology Connection website, discusses an important breakthrough in technology and regenerative medicine. The article provides details of Cardium Therapeutics (NYSE MKT: CXM) and its Generx product candidate, a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease. The article titled, “Cardium Therapeutics reports advance – gene therapy process technology” was written by Rex Graham, a science journalist with a master’s degree in microbiology and a 30-year career Read More |
OTCBB News
read more
Stay Informed
Dana-Farber to Host Cellceutix Trials
Diabetes Rate Growing Exponentially
According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.
